HUTCHMED (China) (HCM) Jefferies Global Healthcare Conference summary

Company overview and strategic focus

• Nearly 25 years of experience, evolving from discovery to commercialization with a strong internal R&D team now numbering about 900.

• Commercial operations have expanded to about 2,000 employees, with 900 focused on sales in China.

• Partnerships with AstraZeneca, Eli Lilly, and Takeda support commercialization and global reach.

Commercial performance and product pipeline

• Three marketed compounds in China: fruquintinib (ELUNATE), surufatinib, and ORPATHYS, all showing robust sales growth.

• Fruquintinib sales exceed $100 million annually, with growth in the mid- to high teens; surufatinib and ORPATHYS growing 30%-40%.

• ORPATHYS' major opportunity lies in combination with TAGRISSO, targeting a large market in the next 18-24 months.

Market dynamics and pricing in China

• Deep market penetration into Tier 2 and 3 cities, leveraging a large sales force and established networks.

• Pricing for key drugs has remained stable through renegotiations, with minimal discounts observed.